AstraZeneca PLC (LON:AZN) Receives £153.33 Average PT from Analysts

AstraZeneca PLC (LON:AZN) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is £153.33.

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research note on Friday, June 26th. Citigroup cut AstraZeneca to a “buy” rating in a report on Friday, July 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 target price on shares of AstraZeneca in a research report on Friday, June 26th.

AstraZeneca Stock Down 1.3%

LON:AZN opened at £127.22 on Tuesday. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66. The stock’s fifty day moving average is £134.89 and its two-hundred day moving average is £140.60. AstraZeneca has a 52 week low of £107.44 and a 52 week high of £157.32. The stock has a market capitalization of £197.30 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.